On May 9, 2024, Bluejay Therapeutics, Inc. closed the transaction. The transaction was led by new investors, Frazier Life Sciences Management, LP and a life science focused institutional investment firm with participation from new investors, RA Capital Management, L.P., T. Rowe Price Group, Inc., Wellington Management Group LLP, Novo Holdings A/S, HBM Healthcare Investments AG, managed by HBM Partners Ltd., Unicorn Capital Partners, returning investors, RiverVest Venture Management LLC, Octagon Capital Advisors LP and Arkin Bio Venture Partners Ltd. Daniel Estes of Frazier Life Sciences Management, LP joined the board of directors. The investment of $181,999,946 pursuant to exemption provided under Regulation D. The transaction included participation from 19 investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
117.6 USD | +0.45% | -0.69% | +9.17% |
Jun. 18 | T. Rowe Price Unveils New, Patent-Pending Framework | CI |
Jun. 12 | Goldman Sachs Raises T. Rowe Price's PT to $113 From $110 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.17% | 26.25B | |
-3.47% | 116B | |
+5.79% | 99.96B | |
+25.89% | 66.76B | |
+4.03% | 64.09B | |
+12.74% | 43.88B | |
+15.07% | 43.41B | |
+28.05% | 37.67B | |
-6.57% | 21.8B | |
-0.37% | 18.37B |
- Stock Market
- Equities
- TROW Stock
- News T. Rowe Price Group Inc.
- Bluejay Therapeutics, Inc. announced that it has received $182.00005 million in funding from a group of investors